

SAFETY DATA SHEET



1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Material	AVANDAMET
Synonym(s)	AVANDIA/METFORMIN COMBINATION TABLET * ROSIGLITAZONE 1 MG + METFORMIN 500 MG TABLET * ROSIGLITAZONE 2 MG + METFORMIN 500 MG TABLET * ROSIGLITAZONE 4 MG + METFORMIN 500 MG TABLET * ROSIGLITAZONE 2 MG + METFORMIN 1000 MG TABLET * ROSIGLITAZONE 4 MG + METFORMIN 1000 MG TABLET * NDC NO. 0007-3167-18 * NDC NO. 0007-3168-18 * NDC NO. 0007-3163-18 * NDC NO. 0007-3164-18 * ROSIGLITAZONE AND METFORMIN, FORMULATED PRODUCT
Company Name	<p>GlaxoSmithKline, Corporate Environment, Health & Safety 980 Great West Road Brentford, Middlesex TW8 9GS UK</p> <p>UK General Information: +44-20-8047-5000 Transport Emergency (EU) +44-1865-407333 Medical Emergency +1-612-221-3999, Ext 221 Information and Advice: US number, available 24 hours Multi-language response</p> <p>GlaxoSmithKline, Corporate Environment, Health & Safety One Franklin Plaza, 200 N 16th Street Philadelphia, PA 19102-1225 US</p> <p>US General Information: +1-888-825-5249 Transport Emergency (non EU) +1-703-527-3887 US number, available 24 hours Multi-language response</p>

2. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredients	CAS #	Percent	EC-No.
METFORMIN HYDROCHLORIDE	1115-70-4	87.7 to 90.9	
NON-HAZARDOUS INGREDIENTS	Unassigned	8.4 to 11.5	
ROSIGLITAZONE MALEATE	155141-29-0	0.5 to 0.9	

3. HAZARDS IDENTIFICATION

Fire and Explosion	Expected to be non-combustible.
Health	Handling this product in its final form presents minimal risk from occupational exposure. Health effects information is based on hazards of components.
Environment	This material contains an active pharmaceutical ingredient that may have reproductive or developmental effects on environmental organisms.

Material AVANDAMET

4. FIRST-AID MEASURES

Ingestion	Never attempt to induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. If the exposed subject is fully conscious, give plenty of water to drink. Obtain medical attention.
Inhalation	Physical form suggests that risk of inhalation exposure is negligible.
Skin Contact	Using appropriate personal protective equipment, remove contaminated clothing and flush exposed area with large amounts of water. Obtain medical attention if skin reaction occurs, which may be immediate or delayed.
Eye Contact	Wash immediately with clean and gently flowing water. Continue for at least 15 minutes. Obtain medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment	Medical treatment in cases of overexposure should be treated as an overdose of a drug for the treatment of Type 2 diabetes. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre.
Medical Conditions Caused or Aggravated by Exposure	None for occupational exposure.
Antidotes	No specific antidotes are recommended.

5. FIRE-FIGHTING MEASURES

Fire and Explosion Hazards	Not expected for the product, although the packaging is combustible.
Extinguishing Media	Water or foam extinguishers are recommended. Carbon dioxide or dry powder extinguishers may be ineffective.
Special Firefighting Procedures	For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapours might be evolved from fires involving this product and associated packaging, self contained breathing apparatus and full protective equipment are recommended for firefighters. If possible, contain and collect firefighting water for later disposal.
Hazardous Combustion Products	Toxic, corrosive or flammable thermal decomposition products are expected when the product is exposed to fire.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions	Wear protective clothing and equipment consistent with the degree of hazard.
Environmental Precautions	For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.
Clean-up Methods	Collect and place it in a suitable, properly labelled container for recovery or disposal.
Decontamination Procedures	No specific decontamination or detoxification procedures have been identified for this product.

7. HANDLING AND STORAGE

HANDLING

General Requirements Avoid breaking or crushing tablets.

STORAGE

No storage requirements necessary for occupational hazards. Follow product information storage instructions to maintain efficacy.

Material AVANDAMET

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

INGREDIENT	ROSIGLITAZONE MALEATE	
GSK Occupational Hazard Category	3	
GSK Occupational Exposure Limit	30 mcg/m ³ (8 HR TWA)	REPRODUCTIVE HAZARD
INGREDIENT	METFORMIN HYDROCHLORIDE	
GSK Occupational Hazard Category	1	
GSK Occupational Exposure Limit	3000 mcg/m ³ (8 HR TWA)	

ENGINEERING CONTROLS

Containment	Open handling may result in overexposure.
Ventilation	Local exhaust ventilation (LEV) should be used in conjunction with other control measures as a means of removing material incidentally released.
Administrative	Entry to the working area should be controlled.
Other Equipment or Procedures	Follow all local regulations if personal protective equipment (PPE) is used in the workplace. Wash hands and arms thoroughly after handling.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance

Physical Form	Tablet.
----------------------	---------

10. STABILITY AND REACTIVITY

Stability	This product is expected to be stable.
Conditions to Avoid	None for normal handling of this product.

11. TOXICOLOGY INFORMATION

Pharmacological Effects	This product contains active ingredient(s) with the following activity: a peroxisome proliferator activated receptor (PPAR) agonist.
Target Organ Effects	No specific target organ effects have been identified.
Routes of Exposure	
Oral Toxicity	Not expected to be toxic following ingestion.
Skin Effects	Minor irritation might occur following direct contact.
Eye Effects	Minor irritation might occur following direct contact with eyes.
Sensitisation	Sensitisation (allergic skin reaction) is not expected.
Genetic Toxicity	Not expected to be genotoxic under occupational exposure conditions.
Carcinogenicity	No components are listed as carcinogens by GSK, IARC, NTP or US OSHA.
Reproductive Effects	Contains components which have been classified as: Possible risk of impaired fertility in human females. Possible risk of toxicity in developing human offspring.
Other Adverse Effects	None known for occupational exposure.

12. ECOLOGICAL INFORMATION

Summary	This material contains two or more active pharmaceutical ingredients that have been tested, one of which may be harmful if released directly to the environment. Specific information on that active pharmaceutical ingredient, Rosiglitazone maleate, is provided below. Consult the MSDS of the active ingredient for specific information about potential environmental effects. Appropriate precautions should be taken to limit release of this material to the environment. Local regulations and procedures should be consulted prior to environmental release.
----------------	--

Material AVANDAMET

ECOTOXICITY**Aquatic****Activated Sludge
Respiration**

This material contains an active pharmaceutical ingredient that is not toxic to activated sludge microorganisms.

IC50: > 1000 mg/L, 3 Hours, Activated sludge, Nominal

Algal

This material contains an active pharmaceutical ingredient that is very toxic to algae.

IC50: 0.88 mg/L, 96 Hours, Selenastrum capricornutum, green algae

NOEC: 0.14 mg/L, 96 Hours, Selenastrum capricornutum, green algae

Daphnid

This material contains an active pharmaceutical ingredient that is toxic to daphnids.

EC50: 6.8 mg/L, 48 Hours, Daphnia magna, Static test

Chronic LOEC: 0.32 mg/l, 7 Days, Ceriodaphnia dubia, 7 day static renewal

Chronic NOEC: 0.1 mg/L, 7 Days, Ceriodaphnia dubia, 7 day static renewal

Fish

No toxicity to fish was observed for the active pharmaceutical ingredient, but the upper range of the test was limited by the low water solubility of the compound.

Juvenile Pimephales promelas, fathead minnow

EC50: > 14.5 mg/L, 96 Hours, Static renewal test

MOBILITY**Solubility**

This material contains an active pharmaceutical ingredient that for environmental fate predictions has limited solubility in water.

Volatility

This material contains an active pharmaceutical ingredient that will not readily enter into air from water.

Henrys Law Constant 1.69E-14 atm m³/mol, Calculated

Adsorption

This material contains an active pharmaceutical ingredient that is not likely to adsorb to sludge or biomass if released directly to the environment.

Soil Sediment Sorption 1.93, Calculated at pH 7 (log Koc):

Sludge Biomass 2.8 Measured

Distribution Coefficient (log Kd):

Partitioning

This material contains an active pharmaceutical ingredient with octanol/water partition coefficient data that suggests that for environmental fate predictions the active pharmaceutical ingredient will not have the tendency to distribute into fats.

PERSISTENCE/DEGRADATION**Biodegradation**

This material contains an active pharmaceutical ingredient that is not readily biodegradable but is inherently biodegradable (as defined by 1993 OECD Testing Guidelines) and is not expected to persist in the environment.

Aerobic - Inherent

Percent Degradation: 50 %, 1 Day, Batch activated sludge (BAS), Activated sludge

Bioaccumulation

This material contains an active pharmaceutical ingredient that will not have a tendency to bioaccumulate in the food chain.

Bioconcentration Factor: 7.6 Calculated

13. DISPOSAL CONSIDERATIONS

Disposal Recommendations

Collect for recycling or recovery if possible. The disposal method for rejected products/returned goods must ensure that they cannot be re-sold or re-used.

Regulatory Requirements

Observe all local and national regulations when disposing of this material.

14. TRANSPORT INFORMATION

The SDS should accompany all shipments for reference in the event of spillage or accidental release. Only authorised persons trained and competent in accordance with appropriate national and international regulatory requirements may prepare dangerous goods for transport.

UN Classification and Labelling

Transport Information

Transportation and shipping of this product is not restricted. It has no known, significant hazards requiring special packaging or labelling for air, maritime, US or European ground transport purposes.

15. REGULATORY INFORMATION

The information included below is an overview of the major regulatory requirements. It should not be considered to be an exhaustive summary. Local regulations should be consulted for additional requirements.

EU Classification and Labelling

Exempt from requirements of EU Dangerous Preparations directive - product regulated as a medicinal product, cosmetic product or medical device.

US OSHA Standard (29 CFR Part 1910.1200)

Classification

This dosage form is exempt from the requirements of the OSHA Hazard Communication Standard.

Other US Regulations

TSCA Status

Exempt

16. OTHER INFORMATION

References

GSK Hazard Determination

SDS Version Number

18

SDS Sections Updated

Sections

COMPOSITION / INFORMATION ON INGREDIENTS

Subsections

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose. For further information please refer to the appropriate product information.